About Eli Lilly and Co
- Industry: Pharmaceuticals
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.lilly.com/
Frequently Asked Questions
What is the 52-week range for LLY?
The 52-week high is $1292.65 and the 52-week low is $763.3.
What is the P/E ratio for LLY?
The Price to Earnings (P/E) ratio is 40.42.
What is the dividend yield for LLY?
The indicated annual dividend yield is 0.75%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 92.58%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 33.53%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 38.29.
Analyst Recommendation Trends
Wall Street analyst consensus for LLY over the last few months:
Latest LLY News
Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study
One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.
Woman, 38, Inherits $1.4M And Finds Her Mom's Advisor Charges 1.25% — Her Brother Says Firing Him Would Be 'Disrespectful'
A 38-year-old woman inherited half of her late mother’s $2.8 million estate, leaving her with a $1.4 million brokerage account still managed by her mom’s longtime advisor. When she finally read the statements, she found a 1.25% annual advisory fee,...
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
The company's search for its next wave of billion-dollar drugs continues.
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Wedbush downgraded Foghorn to ‘Neutral’ from ‘Outperform,’ stating that its bullish thesis no longer applies after the partnership with Lilly ended.
Eli Lilly Stock Is Up 7% in 2026 as Its Obesity Pipeline Expands. Here’s Where the Stock Could Go by 2030
Key Stats for Eli Lilly StockCurrent Price: $1,149. 85Target Price (Mid): ~$2,010Street Target: ~$1,330Potential Total Return: ~75%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly (LLY:NYSE) released Phase 2b results for EloraTZP on September 30.
Chief AI officers arrive in C-suites
Major corporations including Boeing, Eli Lilly, and McDonald’s have added the roles since 2020, the report from Crist Kolder finds.
Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.
3 drug targets pharma is betting on next
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
Correction: Top Midday Decliners
(Corrects the first paragraph to indicate the federal court denied California's request to temporari
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run
Twist Bioscience has turned into one of the market’s stronger long term performers, and the latest surge leaves a simple but important question on the table. Do the company’s current cash flows and their future potential really support today’s share price around US$188? Over the past 3 years, Twist Bioscience has delivered a gain of about 9x, which puts a lot of pressure on its cash flows to justify how far the stock has already run. The new collaboration with Eli Lilly’s TuneLab ties Twist...
GLP-1s: Still Early In The Growth Story
The GLP-1 market continues to expand rapidly yet remains in the early stages of growth. The GLP-1 market is no longer simply a weight-loss story.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades?
The company is constantly thinking big.
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 1% and th
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market
Eli Lilly doubles down on its pipeline with new data for weight-loss pill Foundayo and next-generation combo drug EloraTZP.
Top Midday Decliners
Corteva (CTVA) said Thursday that a federal court in California denied its request to temporarily bl
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says
Eli Lilly's (LLY) new obesity data support a broader drug portfolio beyond tirzepatide, or TZP, UBS
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY4050784), Foghorn and Eli Lilly & Co. (NYSE:LLY) will not advance the program into clinical development expansion. The companies also will not advance their Selective SMARCA2 degrader program and do not
3 takeaways from a European obesity scientific meeting
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).
Lilly, Foghorn part ways; Wave’s FDA-approved plans
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
What Is The Options Market Telling Us About Eli Lilly Stock?
Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review
Foghorn and Lilly will end further collaboration activities after FHD-909 failed to demonstrate sufficient efficacy, while Foghorn cuts its workforce by approximately 40% and extends its cash runway into the second half of 2029. Key Investor TakeawaysFoghorn Therapeutics (NASDAQ:FHTX) and Lilly decided not to advance FHD-909 into clinical expansion following a review of Phase 1 dose-escalation data.
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.
FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?
Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk
Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.
Eli Lilly obesity drug data adds pressure on Novo Nordisk
Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide...
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes.1 Through its proven benefit in weight l
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.,
Top 25 High-Growth Dividend Stocks For October 2026
October 2026 Top 25 High-Growth Dividend Stocks trading 31% below intrinsic value, with a projected 22.53% annual return. Read full analysis here.
Eli Lilly Weight-Loss Drug Foundayo Meets Primary Endpoint in Phase 3 Trial
Eli Lilly's (LLY) weight-loss drug, Foundayo, has met the primary endpoint in a phase 3 trial of adu
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase. The
Novo Announces Wegovy Liver Fat Reductions To Normal Levels In 9 Out Of 10 Adults With Obesity And Excess Liver Fat
Novo Nordisk today presented post hoc analysis of datafrom a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooledsemaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without
Chuck Schumer Slams Hyde Amendment on 50th Anniversary, Says Abortion Restrictions Force Americans to Choose Between Care, Rent, Food: ‘Health Care Must Not Be a Privilege’
Schumer marks 50 years of the Hyde Amendment, criticizing abortion funding restrictions for creating financial barriers to care.
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Could this be what Novo needs to turn things around?
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine in type 2 diabetes to date, Foundayo demonstrated a non-inferior risk of major adverse cardiovascular
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
There could be more catalysts for the biotech over the next 18 months.
Eli Lilly vs. Novo: The Hidden Battle Behind the Weight-Loss Platform Reshaping Industries
GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.
Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading day.
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3
Seven hundred thousand seniors have already started GLP-1s through Medicare, and AstraZeneca just pushed a once-daily pill into late-stage trials. Before you plan your budget around a $50 copay, there are two deadlines that could change everything.
Eli Lilly (LLY) Stock Stays Undervalued As Its 437% Run Raises Stakes
Eli Lilly has become one of the market's most closely watched pharma stocks after a very large multi year run, and the question now is whether the cash it can generate in the future really lines up with the price investors are currently paying. With a Discounted Cash Flow (DCF) lens available, the focus turns to the stream of cash flows implied by that rally rather than the headlines alone. Over the past 5 years, Eli Lilly has delivered a return of about 436.8%, which puts a lot of future...
Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
People with Type 2 diabetes lost an average of nearly 50 pounds on highest dose of Eli Lilly's GLP-1 medication retatrutide, the company said.
Eli Lilly Announces Detailed Results From The Phase 3 ACHIEVE-4 Trial Evaluating The Efficacy And Safety Of Foundayo; Foundayo Experienced A 16% Lower Risk Of MACE-4 And A 23% Lower Risk Of MACE-3, Meeting The Primary Objective For Non-inferiority Compared To Insulin Glargine
Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated
Sector Update: Healthcare Stocks Softer Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
2 Outstanding Dividend Stocks to Buy and Hold for a Decade
There is probably no dividend cut on the horizon for these healthcare companies.
Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug
Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market.
Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.
Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - Slideshow
2026-09-30. The following slide deck was published by Eli Lilly and Company in conjunction with this event.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
Eli Lilly stock rises on striking 23% weight loss in drug combo trial
Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist, in 367 adults with obesity or overweight and type 2 diabetes. At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks
Eli Lilly announced positive Phase 3 trial results for its EBGLYSS dermatitis treatment and its retatrutide obesity and diabetes drug.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Novo Nordisk Wegovy pill weight loss switch study results
A real-world study of 194 patients found those who switched to the daily pill lost an average of 8.8 pounds over 3 months
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Eli Lilly and Company (NYSE: LLY) today announced that EBGLYSS (lebrikizumab-lbkz) monotherapy met its primary and secondary endpoints at Week 16 in the Phase 3b ADtouch study, showing significant and rapid improvements in hand and foot skin clearance, itch and pain in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis (AD). In first-of-its-kind patient satisfaction data for moderate-to-severe hand AD, significantly more patients treated with EBGLYSS were satisfied or
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
CNBC's Annika Kim Constantino reports on Eli Lilly's new combo regiment showed stronger weight loss results than the company's existing obesity drug.
Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis
In first-of-its-kind patient satisfaction data for moderate-to-severe hand AD, significantly more patients treated with EBGLYSS were satisfied or very satisfied with how much the skin on their hands had cleared than
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.
Opinion: Eli Lilly Stock Is a No-Brainer Pick to Buy on the Dip
This stock is worth loading up on whenever it's on the cheap side.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with type 2 diabetes and obesity or overweight. At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and reductions in A1C.1 Results were
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.
Eli Lilly CEO delivers stark message on what comes next
David Ricks says Lilly is looking beyond its recent deals for new growth opportunities.
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.
Eli Lilly Shares Rise After Foundayo Shows More Weight Loss
Eli Lilly Gets a Boost From Foundayo Data Showing More Weight Loss, Better A1C
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy
Zepbound 15 mg was associated with 4.5 percentage points more weight loss than Wegovy HD.
Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit Biologics License Application For Retatrutide In Q1 2027
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesityParticipants with
Prediction: Eli Lilly’s Next Growth Wave Could Surprise Investors
Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that tension shapes whether shares have another 20% to climb or stall near today's levels.
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.
Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge
An indirect comparison favored Foundayo, but no head-to-head trial has established superiority over oral semaglutide.
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
Dear Future Oura Stock Investors, Mark Your Calendars for September 30
Oura is heading toward its Nasdaq debut, giving investors a closer look at its smart ring business and growth prospects.
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.
Weight Watchers Expands GLP-1 Era Strategy With Google Health
Weight Watchers partners with Google Health to integrate Fitbit data and AI insights into select employer programs. WW stock surges 12%.
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline
Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound (tirzepatide) 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss than Wegovy HD (semaglutide injection 7.2 mg) in adults with obesity. The findings come from an indirect treatment comparison of Zepbound and Wegovy HD, drawing on data from the SURMOUNT-1 and STEP UP trials.1,2,3 These results, presented at the 62nd Annual Mee
LLY Vs NVO: Foundayo Beats Novo’s Oral Semaglutide On Weight Loss, Blood Sugar In New Finding
Lilly’s Foundayo 17.2 mg achieved a 1.5% greater weight loss and a 0.3% greater reduction in A1C than oral semaglutide 25 mg after 52 weeks.
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data
Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo Nordisk's semaglutide treatments.
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.
Eli Lilly Launches Global Push to Expand Weight-Loss and Diabetes Drug Access in Lower Income Countries
Eli Lilly launches a global commitment to close the diabetes and obesity treatment gap in low-income countries by 2040.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
What Could Eli Lilly (LLY) New Cancer Win And Deal Shift Mean?
Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm’s current obesity focus. The Breakthrough Therapy status for...
Eli Lilly Announces Results From New Analysis Showing Zepbound 10 Mg And 15 Mg, Dual GIP And GLP-1 Receptor Agonist, Delivered Greater Weight Loss Than Wegovy HD In Adults With Obesity
In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesityParticipants receiving Zepbound 15 mg had more than three times the odds of achieving at least 20% body-weight
Wall Street Breakfast Podcast: Federal Boost For Navitas
A new U.S. government award has Navitas shares surging. After a string of acquisitions, Lilly is hunting for its next big bet. A judge keeps a high-stakes mRNA patent battle alive.
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The findings are based on an indirect treatment comparison of Foundayo 17.2 mg against oral semaglutide 25 mg, drawing on data from ACHIEVE-3 and PIONEER PLUS.1,2,3,4 Presented at the 62nd Annua
Once-Weekly Onswik Approval And Alopecia Win Could Be A Game Changer For Eli Lilly (LLY)
Eli Lilly recently secured U.S. FDA approvals for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, and expanded Olumiant’s label to treat adolescents 12 and older with severe alopecia areata, supported by large Phase 3 programs showing efficacy and consistent safety profiles. Alongside these approvals, Lilly is broadening its pipeline and commercial reach through research collaborations, manufacturing expansion and AI-enabled discovery efforts, indicating a push to...
Eli Lilly's Once-Daily Oral Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg On Weight Loss, A1C At 52 Weeks In Type 2 Diabetes Indirect Comparison Presented At EASD Milan
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeksThese additional analyses build on findings of the ACHIEVE-3 head-to-head study, where
This Stock Could Be the Big Winner Out of Oura’s IPO
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.
$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit
A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index and the State Street Hea
Lilly CEO Reportedly Eyes Bigger ‘White Space’ Deals After A Record 2026 Shopping Spree
Ricks told Bloomberg that the world’s largest drugmaker will keep spending the cash from its weight-loss and diabetes franchise to buy its next act, not just defend the current one.
If You Invested $1000 In Eli Lilly Stock 10 Years Ago, You Would Have This Much Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 17.2% on an annualized basis producing an average annual return of 30.75%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.
Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
Novo Nordisk (NYSE:NVO) finally has a CagriSema result it can put next to Eli Lilly’s (NYSE:LLY) tirzepatide and come out ahead. In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes taking the 1 mg/ 1 mg dose of CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with […]
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.
Lilly CEO Eyes Bigger Deals in Hunt for Pharma’s ‘White Spaces’
Investors should expect Eli Lilly & Co. to strike slightly larger deals, along the lines of its $7.8 billion acquisition of Centessa Pharmaceuticals Plc, as it casts a wide net for assets in the “white spaces” of science, Chief Executive Officer Dave Ricks said.
Kirsten Harmon Joins Vinson & Elkins as NY-Based Corporate Partner
By Karen Roman Vinson & Elkins said Kirsten Harmon is the firm’s latest New York-based partner in its Corporate practice, having previously served at as partner at Simpson Thacher & Bartlett. Ms. Harmon has experience on a broad range of capital markets transactions, including initial public offerings, high-yield debt, and equity and equity-linked securities offerings, […] The post Kirsten Harmon Joins Vinson & Elkins as NY-Based Corporate Partner appeared first on ExecEdge.
He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
A pipefitter switching contractors during construction of a massive new pharmaceutical plant could walk away from tax season with a surprise windfall, and most workers in the same situation never even realize the money exists.
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
"Lilly CEO Eyes Bigger Deals in Hunt for Pharma’s ‘White Spaces’" - Bloomberg News
https://www.bloomberg.com/news/articles/2026-09-28/lilly-ceo-eyes-bigger-deals-in-hunt-for-pharma-s-white-spaces
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
Eli Lilly (NYSE:LLY) Offers a Breakout Setup Backed by High Growth Momentum
Eli Lilly (LLY) shows strong growth, high momentum, and an 8/8 technical/setup profile, offering a defined breakout entry with support levels.
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real question about whether this pause signals opportunity or a longer stall ahead.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
Viking Therapeutics' VK2735 obesity trial shows strong weight loss and better tolerability. Read the latest analysis on the VKTX stock here.
8 Of 11 Sectors Fall In Monday Trading As Defensives Lead
Three sectors are higher and eight are lower in Monday’s regular session, with defensive and cyclical sectors split across the top three positions. The leaders are separated rather than clustered.
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Eli Lilly and Company (NYSE: LLY) is launching today the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated with Lilly's innovative diabetes and obesity medicines. This means treating as many people with diabetes and obesity in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries before 2040. Today, for every 4 people in high-income countries who have access to Lilly's diabetes a
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Rising Yields and Trump's Rejection of Hormuz Deal Spook Investors — LLY, PEP, JEF in Focus (UPDATED)
U.S. stock futures declined on Monday, as the Dow Jones, S&P 500, and Nasdaq 100 indices fell, following Friday's higher close.
Eli Lilly Just Announced Game-Changing News
Something new is happening in the weight loss drug market.
Eli Lilly Wins FDA Approval for Weekly Insulin. Here’s What Comes Next
Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.
An Investor's Guide To Intangible Assets
Intangible assets are non-physical assets that bring value to a company but lack a physical presence. Read more here.
Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?
On September 25, Eli Lilly and Company (NYSE:LLY) announced that the U.S. FDA approved Olumiant (baricitinib), a once-daily pill, for pediatric patients 12 years of age and older with severe alopecia areata (AA). The decision expands Olumiant’s label beyond established adult indications in moderately to severely active rheumatoid arthritis and severe AA, enlarging its addressable […]
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?
A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S (NYSE:NVO) is now facing them from its own investors. Late September 2026 brought renewed pressure on the company to explain what comes after its weight-loss drug franchise, as analysts project Eli Lilly’s […]
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On the other hand, Medtronic’s growth is spread across a much broader […]
A New Wave of Senior Patients Could Extend Lilly’s GLP-1 Growth Story
Eli Lilly and Company (NYSE:LLY) CEO David Ricks said that about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July, with roughly 70% using Lilly medicines. The temporary Medicare “Bridge” program allows eligible beneficiaries to obtain obesity treatments for a $50 monthly co-pay, giving Zepbound and Foundayo access to […]
Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?
Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks told CNBC that Foundayo now accounts for roughly one-third of new patients starting an oral GLP-1, with Lilly’s share of the pill market increasing week over week. The update comes as Lilly broke ground on a $6.5 billion manufacturing facility in Houston that is expected to be […]
Novo Nordisk Searches for Growth Beyond its Biggest Franchise
Novo Nordisk A/S (NYSE:NVO) is defending its push to diversify beyond obesity as CEO Mike Doustdar signals that the company is willing to pursue deals to build growth outside its core weight-loss franchise. At its September 2026 Capital Markets Day, Novo said it aims to launch more than five multi-blockbuster medicines by 2030 and generate […]
Eli Lilly Stock Is Up 31% in Six Months. Next Week’s Obesity Data Is the Next Test.
Key TakeawaysEli Lilly stock has climbed 31% over the past six months, though shares sit only ~7% above their 2026 starting level as of September 23. Q2 revenue jumped 48% YoY, and management raised full-year revenue guidance to $85B-$87B.
Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200
The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the needle on a stock already up 60% and closing in on record highs.
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.
Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?
Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the pharma stock. But perhaps the more important change was in Foundayo estimates. Guggenheim sharply raised its revenue forecasts for Lilly’s oral obesity drug, […]
Here's Where Wall Street Analysts See Eli Lilly's Share Price Going
Eli Lilly's share price climb has decelerated in 2026.
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.
MarketBeat Week in Review – 09/21 - 09/25
A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.
Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]
Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding a new dosing option. Eli Lilly agreed a global drug discovery alliance with InnoCare Pharma valued at up to US$3.35b in research and licensing commitments. These combined FDA approvals and the US$3.35b InnoCare alliance deserve weighing against the rest of our Eli Lilly analysis. We have also...
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA).1 The approval expands Olumiant's U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA.
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
How to make sense of 7% mortgage rates and Oracle's AI data center disruption
In this episode of Market Hang, Turney Duff and his panel of experts weigh in on Oracle's (ORCL) recent data center hiccups, high mortgage rates, McDonald's (MCD) as a market play, and more.Today's panel includes Exhibit A co-founder Matt Cerminaro, Fundstrat economic strategist Hardika Singh, YouTuber and financial adviser Kevin Paffrath, and Yahoo Finance Executive Editor Brian Sozzi.
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street
Eli Lilly Receives FDA Approval For Olumiant In Pediatric Patients Aged 12 And Older With Severe Alopecia Areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA)Treatment with Olumiant resulted in
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 38% over the past six months while the S&P 500 was up 16.9%.
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY).
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect
91-year-old investor sees healthcare titan doubling in 3 years
The billionaire Home Depot co-founder has held the stock since 1977. Here’s where he thinks it’s going.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The biotech player could eventually rival big pharma companies.
Novo Signs $1.3 Billion Nanexa Deal for Long-Acting Drugs
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisitions as the Danish company tries to ensure it can grow through a looming patent cliff.
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type 2 diabetes, giving patients an alternative to daily long-acting insulin shots. According to Reuters, Lilly said Onswik — chemically known as insulin efsitora alfa-gobe — is intended to be used with diet and exercise to help control high blood sugar and could cut the number of inje
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
Eli Lilly breaks ground on $6.5B Houston manufacturing plant
Bechtel’s manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general contractor.
Medicare just handed Eli Lilly a massive weight-loss win
As Medicare Bridge participation surges, Novo Nordisk’s share of those new patients is drawing attention.
Lilly Jumps 3.64% While a $100 Billion Obesity Race Crowds In
New pills, injections and maintenance regimens broaden patient choice while raising the durability test for market leaders.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B
Lilly will pay $100 million upfront to work with the Beijing-based biotech on as many as five undisclosed drug targets
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104. Click to read in detail about ACIU.
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments.
Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight
Treatment of chronic kidney disease (CKD) focuses on slowing disease progression toward kidney failure, reducing cardiovascular risk, and addressing complications such as anemia and mineral bone disorders. SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and emerging aldosterone synthase inhibitor combinations are increasingly replacing single-agent RAS blockade, driven by their improved renal and cardiovascular outcomes. Approved therapies in the CKD market include
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact
Eli Lilly secured FDA approval for its once-weekly insulin Onswik and announced a $3.25 billion research partnership with InnoCare Pharma.
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
SAN MATEO, Calif., September 24, 2026--BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, today announced the completion of a $75 million Series C financing, bringing its total funding raised to date to $223 million. The round was co-led by DFJ Growth & Premji Invest with participation from Catalio Capital Management, LG Technology Ventures, Sigmas Group, and existing investors including 8VC, Alexandria Venture Investments, Amgen Ventures, Andreessen Horowitz
ISPE Announces its 2026 ISPE Annual Meeting & Expo Keynote Speakers
The International Society for Pharmaceutical Engineering (ISPE) has announced its planned keynote speakers for its largest event of the year, the 2026 ISPE Annual Meeting & Expo. The conference will take place from 18–21 October in Washington, D.C., USA, and virtually.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
The FDA Approves Eli Lilly's Onswik (Insulin Efsitora Alfa-gobe) For Type 2 Diabetes
Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”) to develop new medicines. InnoCare will leverage its proprietary drug discovery platform and extensive research experience to discover and advance compounds against up to
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
Bill Ackman Calls AI’s Rare-Disease Breakthrough ‘Incredible’ After Model Finds Drug Combination for Dying Patient
Bill Ackman highlighted a case where AI identified an untried drug combination that helped a dying rare-disease patient recover.
Could Retatrutide Be Worth $10 Billion to Eli Lilly?
The company continues to dominate the weight loss market.
Lilly Slips as $6.5 Billion Plant Backs Oral GLP-1 Scale
Houston will produce Foundayo ingredients, linking manufacturing capacity directly to Lilly's planned global rollout.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735. Click for more.
Lilly stopped showing its phase 1 pipeline. Is it playing R&D chess?
Lilly no longer publicly lists its earliest clinical programs. The move could buy the pharma giant time to test, kill and reposition drugs while competitors are still reading the board.
AutoZone (AZO) Posts Strong Earnings, But Is the Stock Ready to Rebound?
On September 22, AutoZone, Inc. (NYSE:AZO) reported results for its fourth quarter, which covered 16 weeks and ended August 29, 2026. The company delivered stronger-than-expected profits and the stock ended the session 3.26% higher. The company’s net sales increased 5.6% year-over-year to $6.6 billion, while operating profit rose 10.1% to $1.3 billion. Net income reached […]
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets
Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipelineAX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development pro
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva
Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.
Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'
Eli Lilly and Co.‘s CEO Dave Ricks announced a significant increase in the use of GLP-1 treatments among seniors, following Medicare’s July decision to cover obesity drugs. On Monday, Ricks said in an interview with CNBC that 70% of the...
Viking Therapeutics Soars as Weight-Loss Drug Trial Addresses GLP-1 Weakness
Research has shown the adherence rates of patients on GLP-1 therapies can fall as low as 27% after one year.
Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone
Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.
Obesity titan could shake up Lilly and Novo after astonishing trial
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Eli Lilly CEO reveals astonishing shift in GLP-1 pill market
Medicare coverage opens the obesity pill market to millions more Americans.
Lilly Rises Higher as Viking Preserves Up to 90% Monthly
Less-frequent injections could challenge chronic-treatment economics long before Viking reaches the market.
Novo Nordisk Just Made a Surprising Move Beyond Weight Loss
The company aims to launch more than five potential blockbuster drugs by 2030.
Should Eli Lilly (LLY) Investors Watch Its $6.5 Billion Houston GLP 1 Buildout?
Eli Lilly (NYSE: LLY) has started construction on a US$6.5b manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The new site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. This large Houston buildout for Foundayo is an important piece to weigh alongside the rest of our...
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.
Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.
Eli Lilly Breaks Ground on $6.5B Generation Park Facility
A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000
Ken Langone built a fortune betting on Home Depot decades before anyone called it a sure thing, and now he says another stock in his portfolio is giving it a serious run for the top spot.
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Viking Therapeutics Stock Surges 30%. It Could Challenge Lilly and Novo’s Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer
The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.
Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial
Roche (USOTC:RHHBY) has reported positive results from a mid-stage clinical trial of its experimental obesity treatment enicepatide, with patients who have type 2 diabetes achieving average weight loss of 15. 5% alongside improvements in blood sugar control.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
Eli Lilly CEO Dave Ricks: 70% of new Medicare GLP-1 patients on Lilly drugs
CEO Dave Ricks told CNBC that 700,000 seniors have started weight loss treatments since Medicare coverage launched in July
Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill
Eli Lilly Stock Gets Powerful Boost From Foundayo as Oral Weight-Loss Pill Gains Ground
Eli Lilly Just Got a Big Boost From Medicare's GLP-1 Expansion
About 700,000 seniors have started GLP-1 treatments since Medicare coverage began in July.
VKTX Stock Spikes 38% Premarket: Viking’s VK2735 Shows Promise For Weight-Loss Maintenance
Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer, and Ajay Nirula, M.D., Ph.D., president and head of research and development, will present an overview of the company at the Oppenheimer Private Life Sciences Company Showcase. The company’s presentation will be on Tuesday, September 29, 20
Novo targets blockbuster-heavy 2030 but share slump signals unease
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.
Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the selloff created the most compelling entry point in the GLP-1 giant's recent history.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | LUCIANO JUAN R | +14 | $1164.89 | $16,308 |
| 2026-09-21 | Fyrwald J Erik | +9 | $1164.89 | $10,484 |
| 2026-09-21 | Alvarez Ralph | +11 | $1164.89 | $12,814 |
| 2026-09-21 | Sulzberger Gabrielle | +4 | $1164.89 | $4,660 |
| 2026-09-09 | Seymour Melissa | -12 | - | - |
| 2026-09-02 | Dozier Eric | -216 | - | - |
| 2026-09-02 | Hernandez Edgardo | -13 | - | - |
| 2026-08-17 | Jonsson Patrik | -6,500 | $1175.1 | $7,638,150 |
| 2026-08-17 | LUCIANO JUAN R | +13 | $1183.16 | $15,381 |
| 2026-08-17 | Fyrwald J Erik | +8 | $1183.16 | $9,465 |
| 2026-08-17 | Alvarez Ralph | +10 | $1183.16 | $11,832 |
| 2026-08-17 | Sulzberger Gabrielle | +4 | $1183.16 | $4,733 |
| 2026-08-10 | Zakrowski Donald A | -2,000 | $1185.01 | $2,370,020 |
| 2026-08-07 | Hakim Anat | -5,000 | $1190 | $5,950,000 |
| 2026-08-01 | Seymour Melissa | -981 | - | - |
| 2026-08-01 | Seymour Melissa | -439 | $1148.84 | $504,341 |
| 2026-08-01 | Seymour Melissa | +981 | - | - |
| 2026-07-20 | LUCIANO JUAN R | +14 | $1146.9 | $16,057 |
| 2026-07-20 | Fyrwald J Erik | +9 | $1146.9 | $10,322 |
| 2026-07-20 | Alvarez Ralph | +11 | $1146.9 | $12,616 |
| 2026-07-20 | Sulzberger Gabrielle | +4 | $1146.9 | $4,588 |
| 2026-06-15 | LUCIANO JUAN R | +14 | $1129.35 | $15,811 |
| 2026-06-15 | Fyrwald J Erik | +9 | $1129.35 | $10,164 |
| 2026-06-15 | Alvarez Ralph | +11 | $1129.35 | $12,423 |
| 2026-06-15 | Sulzberger Gabrielle | +4 | $1129.35 | $4,517 |
| 2026-06-10 | Yuffa Ilya | -2,500 | $1150.77 | $2,876,925 |
| 2026-05-18 | LUCIANO JUAN R | +16 | $988.09 | $15,809 |
| 2026-05-18 | Fyrwald J Erik | +10 | $988.09 | $9,881 |
| 2026-05-18 | Alvarez Ralph | +13 | $988.09 | $12,845 |
| 2026-05-18 | Sulzberger Gabrielle | +5 | $988.09 | $4,940 |
| 2026-05-06 | LILLY ENDOWMENT INC | -2,208 | $996.183 | $2,199,572 |
| 2026-05-06 | LILLY ENDOWMENT INC | -13,620 | $995.225 | $13,554,965 |
| 2026-04-20 | LUCIANO JUAN R | +17 | $919.9 | $15,638 |
| 2026-04-20 | Fyrwald J Erik | +11 | $919.9 | $10,119 |
| 2026-04-20 | Alvarez Ralph | +13 | $919.9 | $11,959 |
| 2026-04-20 | Sulzberger Gabrielle | +5 | $919.9 | $4,600 |
| 2026-03-16 | LUCIANO JUAN R | +16 | $989.12 | $15,826 |
| 2026-03-16 | Fyrwald J Erik | +10 | $989.12 | $9,891 |
| 2026-03-16 | Alvarez Ralph | +13 | $989.12 | $12,859 |
| 2026-03-16 | Sulzberger Gabrielle | +5 | $989.12 | $4,946 |
| 2026-02-19 | Dozier Eric | -481 | - | - |
| 2026-02-17 | LUCIANO JUAN R | +15 | $1036.05 | $15,541 |
| 2026-02-17 | Fyrwald J Erik | +10 | $1036.05 | $10,361 |
| 2026-02-17 | Alvarez Ralph | +12 | $1036.05 | $12,433 |
| 2026-02-17 | Sulzberger Gabrielle | +5 | $1036.05 | $5,180 |
| 2026-02-16 | Brown Adrienne S | -391 | - | - |
| 2026-02-16 | Brown Adrienne S | -170 | $1040 | $176,800 |
| 2026-02-16 | Brown Adrienne S | +391 | - | - |
| 2026-02-16 | Custer Kenneth L. | -207 | - | - |
| 2026-02-16 | Custer Kenneth L. | -91 | $1040 | $94,640 |
| 2026-02-16 | Custer Kenneth L. | +207 | - | - |
| 2026-02-16 | Montarce Lucas | -368 | - | - |
| 2026-02-16 | Montarce Lucas | -160 | $1040 | $166,400 |
| 2026-02-16 | Montarce Lucas | +368 | - | - |
| 2026-02-16 | Zakrowski Donald A | -184 | - | - |
| 2026-02-16 | Zakrowski Donald A | -82 | $1040 | $85,280 |
| 2026-02-16 | Zakrowski Donald A | +184 | - | - |
| 2026-02-09 | Rau Diogo | +4,599 | $1044.67 | $4,804,437 |
| 2026-02-09 | Brown Adrienne S | +1,196 | $1044.67 | $1,249,425 |
| 2026-02-09 | Custer Kenneth L. | +659 | $1044.67 | $688,438 |
| 2026-02-09 | Dozier Eric | +3,512 | $1044.67 | $3,668,881 |
| 2026-02-09 | Hernandez Edgardo | +4,384 | $1044.67 | $4,579,833 |
| 2026-02-09 | Rau Diogo | +4,432 | $1044.67 | $4,629,977 |
| 2026-02-09 | Yuffa Ilya | +4,163 | $1044.67 | $4,348,961 |
| 2026-02-09 | Jonsson Patrik | +4,818 | $1044.67 | $5,033,220 |
| 2026-02-09 | Montarce Lucas | +1,365 | $1044.67 | $1,425,975 |
| 2026-02-09 | Skovronsky Daniel | +15,548 | $1044.67 | $16,242,529 |
| 2026-02-09 | Hakim Anat | +8,278 | $1044.67 | $8,647,778 |
| 2026-02-09 | Van Naarden Jacob | +4,866 | $1044.67 | $5,083,364 |
| 2026-02-09 | Zakrowski Donald A | +199 | - | - |
| 2026-02-09 | Zakrowski Donald A | +584 | $1044.67 | $610,087 |
| 2026-02-09 | Ricks David A | +38,914 | $1044.67 | $40,652,288 |
| 2026-02-01 | Dozier Eric | -2,858 | - | - |
| 2026-02-01 | Dozier Eric | -1,273 | $1037.15 | $1,320,292 |
| 2026-02-01 | Dozier Eric | +2,858 | - | - |
| 2026-02-01 | Hernandez Edgardo | -3,572 | - | - |
| 2026-02-01 | Hernandez Edgardo | -1,591 | $1037.15 | $1,650,106 |
| 2026-02-01 | Hernandez Edgardo | +3,572 | - | - |
| 2026-02-01 | Rau Diogo | -3,752 | - | - |
| 2026-02-01 | Rau Diogo | -1,674 | $1037.15 | $1,736,189 |
| 2026-02-01 | Rau Diogo | +3,752 | - | - |
| 2026-02-01 | Yuffa Ilya | -3,394 | - | - |
| 2026-02-01 | Yuffa Ilya | -1,512 | $1037.15 | $1,568,171 |
| 2026-02-01 | Yuffa Ilya | +3,394 | - | - |
| 2026-02-01 | Jonsson Patrik | -3,930 | - | - |
| 2026-02-01 | Jonsson Patrik | -1,752 | $1037.15 | $1,817,087 |
| 2026-02-01 | Jonsson Patrik | +3,930 | - | - |
| 2026-02-01 | Skovronsky Daniel | -12,684 | - | - |
| 2026-02-01 | Skovronsky Daniel | -5,641 | $1037.15 | $5,850,563 |
| 2026-02-01 | Skovronsky Daniel | +12,684 | - | - |
| 2026-02-01 | Hakim Anat | -6,700 | - | - |
| 2026-02-01 | Hakim Anat | -2,953 | $1037.15 | $3,062,704 |
| 2026-02-01 | Hakim Anat | +6,700 | - | - |
| 2026-02-01 | Van Naarden Jacob | -4,108 | - | - |
| 2026-02-01 | Van Naarden Jacob | -1,909 | $1037.15 | $1,979,919 |
| 2026-02-01 | Van Naarden Jacob | +4,108 | - | - |
| 2026-02-01 | Ricks David A | -31,932 | - | - |
| 2026-02-01 | Ricks David A | -14,297 | $1037.15 | $14,828,134 |
| 2026-02-01 | Ricks David A | +31,932 | - | - |
| 2026-01-20 | LUCIANO JUAN R | +15 | $1041.29 | $15,619 |
| 2026-01-20 | Fyrwald J Erik | +10 | $1041.29 | $10,413 |
| 2026-01-20 | Alvarez Ralph | +12 | $1041.29 | $12,495 |
| 2026-01-20 | Sulzberger Gabrielle | +5 | $1041.29 | $5,206 |
| 2026-01-07 | LILLY ENDOWMENT INC | -2,737 | $1116.686 | $3,056,370 |
| 2026-01-07 | LILLY ENDOWMENT INC | -2,210 | $1115.761 | $2,465,832 |
| 2026-01-07 | LILLY ENDOWMENT INC | -4,342 | $1114.372 | $4,838,603 |
| 2026-01-07 | LILLY ENDOWMENT INC | -9,053 | $1113.771 | $10,082,969 |
| 2026-01-07 | LILLY ENDOWMENT INC | -4,652 | $1112.433 | $5,175,038 |
| 2026-01-07 | LILLY ENDOWMENT INC | -2,085 | $1111.214 | $2,316,881 |
| 2026-01-07 | LILLY ENDOWMENT INC | -3,464 | $1110.367 | $3,846,311 |
| 2026-01-07 | LILLY ENDOWMENT INC | -8,513 | $1109.318 | $9,443,624 |
| 2026-01-07 | LILLY ENDOWMENT INC | -13,247 | $1108.415 | $14,683,174 |
| 2026-01-07 | LILLY ENDOWMENT INC | -16,650 | $1107.371 | $18,437,727 |
| 2026-01-07 | LILLY ENDOWMENT INC | -13,701 | $1106.416 | $15,159,006 |
| 2026-01-07 | LILLY ENDOWMENT INC | -24,362 | $1105.456 | $26,931,119 |
| 2026-01-07 | LILLY ENDOWMENT INC | -21,042 | $1104.403 | $23,238,848 |
| 2026-01-07 | LILLY ENDOWMENT INC | -40,956 | $1103.313 | $45,187,287 |
| 2026-01-07 | LILLY ENDOWMENT INC | -34,434 | $1102.411 | $37,960,420 |
| 2026-01-07 | LILLY ENDOWMENT INC | -20,668 | $1101.423 | $22,764,211 |
| 2026-01-07 | LILLY ENDOWMENT INC | -14,937 | $1100.459 | $16,437,556 |
| 2026-01-07 | LILLY ENDOWMENT INC | -20,447 | $1099.361 | $22,478,634 |
| 2026-01-07 | LILLY ENDOWMENT INC | -9,573 | $1098.552 | $10,516,438 |
| 2026-01-07 | LILLY ENDOWMENT INC | -6,408 | $1097.412 | $7,032,216 |
| 2026-01-07 | LILLY ENDOWMENT INC | -475 | $1095.738 | $520,476 |
| 2026-01-07 | LILLY ENDOWMENT INC | -420 | $1094.701 | $459,774 |
| 2026-01-07 | LILLY ENDOWMENT INC | -1,322 | $1093.584 | $1,445,718 |
| 2026-01-07 | LILLY ENDOWMENT INC | -1,072 | $1092.557 | $1,171,221 |
| 2026-01-07 | LILLY ENDOWMENT INC | -1,224 | $1091.048 | $1,335,443 |
| 2026-01-07 | LILLY ENDOWMENT INC | -3,575 | $1090.183 | $3,897,404 |
| 2026-01-07 | LILLY ENDOWMENT INC | -930 | $1088.967 | $1,012,739 |
| 2026-01-07 | LILLY ENDOWMENT INC | -1,070 | $1087.801 | $1,163,947 |
| 2026-01-07 | LILLY ENDOWMENT INC | -7,684 | $1086.748 | $8,350,572 |
| 2026-01-07 | LILLY ENDOWMENT INC | -895 | $1085.108 | $971,172 |
| 2026-01-05 | LILLY ENDOWMENT INC | -1,390 | $1085.011 | $1,508,165 |
| 2025-12-29 | LILLY ENDOWMENT INC | -3,593 | $1085.035 | $3,898,531 |
| 2025-12-24 | LILLY ENDOWMENT INC | -2,629 | $1085.173 | $2,852,920 |
| 2025-12-23 | LILLY ENDOWMENT INC | -240 | $1085.038 | $260,409 |
| 2025-12-15 | LUCIANO JUAN R | +14 | $1062.19 | $14,871 |
| 2025-12-15 | Fyrwald J Erik | +9 | $1062.19 | $9,560 |
| 2025-12-15 | Hedley Mary Lynne | +9 | $1062.19 | $9,560 |
| 2025-12-15 | Alvarez Ralph | +11 | $1062.19 | $11,684 |
| 2025-12-15 | Sulzberger Gabrielle | +5 | $1062.19 | $5,311 |
| 2025-11-25 | LILLY ENDOWMENT INC | -1,340 | $1110.527 | $1,488,106 |
| 2025-11-25 | LILLY ENDOWMENT INC | -9,249 | $1109.449 | $10,261,294 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,043 | $1108.71 | $5,591,225 |
| 2025-11-25 | LILLY ENDOWMENT INC | -7,794 | $1107.48 | $8,631,699 |
| 2025-11-25 | LILLY ENDOWMENT INC | -3,662 | $1106.573 | $4,052,270 |
| 2025-11-25 | LILLY ENDOWMENT INC | -2,494 | $1105.32 | $2,756,668 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,196 | $1104.411 | $5,738,520 |
| 2025-11-25 | LILLY ENDOWMENT INC | -6,274 | $1103.576 | $6,923,836 |
| 2025-11-25 | LILLY ENDOWMENT INC | -7,456 | $1102.346 | $8,219,092 |
| 2025-11-25 | LILLY ENDOWMENT INC | -11,854 | $1101.449 | $13,056,576 |
| 2025-11-25 | LILLY ENDOWMENT INC | -8,527 | $1100.336 | $9,382,565 |
| 2025-11-25 | LILLY ENDOWMENT INC | -6,545 | $1099.485 | $7,196,129 |
| 2025-11-25 | LILLY ENDOWMENT INC | -4,639 | $1098.315 | $5,095,083 |
| 2025-11-25 | LILLY ENDOWMENT INC | -4,198 | $1097.443 | $4,607,066 |
| 2025-11-25 | LILLY ENDOWMENT INC | -1,061 | $1096.329 | $1,163,205 |
| 2025-11-25 | LILLY ENDOWMENT INC | -2,083 | $1094.794 | $2,280,456 |
| 2025-11-25 | LILLY ENDOWMENT INC | -6,246 | $1094.026 | $6,833,286 |
| 2025-11-25 | LILLY ENDOWMENT INC | -9,050 | $1093.164 | $9,893,134 |
| 2025-11-25 | LILLY ENDOWMENT INC | -18,254 | $1092.058 | $19,934,427 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,927 | $1091.116 | $6,467,045 |
| 2025-11-25 | LILLY ENDOWMENT INC | -1,907 | $1089.854 | $2,078,352 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,284 | $1088.907 | $5,753,785 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,589 | $1087.965 | $6,080,636 |
| 2025-11-25 | LILLY ENDOWMENT INC | -6,508 | $1086.941 | $7,073,812 |
| 2025-11-25 | LILLY ENDOWMENT INC | -5,604 | $1086.069 | $6,086,331 |
| 2025-11-25 | LILLY ENDOWMENT INC | -3,069 | $1084.702 | $3,328,950 |
| 2025-11-25 | LILLY ENDOWMENT INC | -160 | $1082.933 | $173,269 |
| 2025-11-25 | LILLY ENDOWMENT INC | -1,606 | $1081.9 | $1,737,531 |
| 2025-11-25 | LILLY ENDOWMENT INC | -651 | $1080.733 | $703,557 |
| 2025-11-25 | LILLY ENDOWMENT INC | -1,260 | $1079.367 | $1,360,002 |
| 2025-11-25 | LILLY ENDOWMENT INC | -800 | $1077.988 | $862,390 |
| 2025-11-25 | LILLY ENDOWMENT INC | -882 | $1075.997 | $949,029 |
| 2025-11-25 | LILLY ENDOWMENT INC | -2,481 | $1073.735 | $2,663,937 |
| 2025-11-24 | LILLY ENDOWMENT INC | -2,954 | $1073.597 | $3,171,406 |
| 2025-11-24 | LILLY ENDOWMENT INC | -744 | $1072.776 | $798,145 |
| 2025-11-24 | LILLY ENDOWMENT INC | -1,710 | $1071.369 | $1,832,041 |
| 2025-11-24 | LILLY ENDOWMENT INC | -2,778 | $1070.351 | $2,973,435 |
| 2025-11-24 | LILLY ENDOWMENT INC | -14,105 | $1069.477 | $15,084,973 |
| 2025-11-24 | LILLY ENDOWMENT INC | -120,016 | $1068.175 | $128,198,091 |
| 2025-11-21 | LILLY ENDOWMENT INC | -160 | $1066.15 | $170,584 |
| 2025-11-21 | LILLY ENDOWMENT INC | -1,459 | $1065.569 | $1,554,665 |
| 2025-11-21 | LILLY ENDOWMENT INC | -3,378 | $1064.433 | $3,595,655 |
| 2025-11-21 | LILLY ENDOWMENT INC | -8,576 | $1063.572 | $9,121,193 |
| 2025-11-21 | LILLY ENDOWMENT INC | -9,051 | $1062.517 | $9,616,841 |
| 2025-11-21 | LILLY ENDOWMENT INC | -10,492 | $1061.559 | $11,137,877 |
| 2025-11-21 | LILLY ENDOWMENT INC | -7,582 | $1060.531 | $8,040,946 |
| 2025-11-21 | LILLY ENDOWMENT INC | -23,916 | $1059.658 | $25,342,781 |
| 2025-11-21 | LILLY ENDOWMENT INC | -9,729 | $1058.461 | $10,297,767 |
| 2025-11-21 | LILLY ENDOWMENT INC | -5,064 | $1057.584 | $5,355,605 |
| 2025-11-21 | LILLY ENDOWMENT INC | -1,546 | $1056.396 | $1,633,188 |
| 2025-11-21 | LILLY ENDOWMENT INC | -2,495 | $1055.452 | $2,633,353 |
| 2025-11-21 | LILLY ENDOWMENT INC | -1,629 | $1054.422 | $1,717,653 |
| 2025-11-21 | LILLY ENDOWMENT INC | -1,987 | $1053.458 | $2,093,221 |
| 2025-11-21 | LILLY ENDOWMENT INC | -2,885 | $1052.361 | $3,036,061 |
| 2025-11-21 | LILLY ENDOWMENT INC | -5,506 | $1051.484 | $5,789,471 |
| 2025-11-21 | LILLY ENDOWMENT INC | -9,871 | $1050.272 | $10,367,235 |
| 2025-11-20 | LILLY ENDOWMENT INC | -665 | $1055.391 | $701,835 |
| 2025-11-20 | LILLY ENDOWMENT INC | -3,188 | $1054.508 | $3,361,772 |
| 2025-11-20 | LILLY ENDOWMENT INC | -3,702 | $1053.522 | $3,900,138 |
| 2025-11-20 | LILLY ENDOWMENT INC | -6,047 | $1052.545 | $6,364,740 |
| 2025-11-20 | LILLY ENDOWMENT INC | -6,701 | $1051.373 | $7,045,250 |
| 2025-11-20 | LILLY ENDOWMENT INC | -16,845 | $1050.364 | $17,693,382 |
| 2025-11-19 | LILLY ENDOWMENT INC | -1,206 | $1055.081 | $1,272,428 |
| 2025-11-19 | LILLY ENDOWMENT INC | -6,109 | $1054.483 | $6,441,837 |
| 2025-11-19 | LILLY ENDOWMENT INC | -13,820 | $1053.474 | $14,559,011 |
| 2025-11-19 | LILLY ENDOWMENT INC | -21,107 | $1052.537 | $22,215,898 |
| 2025-11-19 | LILLY ENDOWMENT INC | -28,768 | $1051.434 | $30,247,653 |
| 2025-11-19 | LILLY ENDOWMENT INC | -96,516 | $1050.208 | $101,361,875 |
| 2025-11-18 | LILLY ENDOWMENT INC | -980 | $1039.61 | $1,018,818 |
| 2025-11-18 | LILLY ENDOWMENT INC | -3,950 | $1038.48 | $4,101,996 |
| 2025-11-18 | LILLY ENDOWMENT INC | -2,424 | $1037.379 | $2,514,607 |
| 2025-11-18 | LILLY ENDOWMENT INC | -8,067 | $1036.576 | $8,362,059 |
| 2025-11-18 | LILLY ENDOWMENT INC | -13,097 | $1035.501 | $13,561,957 |
| 2025-11-18 | LILLY ENDOWMENT INC | -12,198 | $1034.652 | $12,620,685 |
| 2025-11-18 | LILLY ENDOWMENT INC | -6,380 | $1033.497 | $6,593,711 |
| 2025-11-18 | LILLY ENDOWMENT INC | -7,208 | $1032.635 | $7,443,233 |
| 2025-11-18 | LILLY ENDOWMENT INC | -1,605 | $1031.414 | $1,655,419 |
| 2025-11-18 | LILLY ENDOWMENT INC | -4,304 | $1030.317 | $4,434,484 |
| 2025-11-17 | LILLY ENDOWMENT INC | -2,097 | $1031.526 | $2,163,110 |
| 2025-11-17 | LILLY ENDOWMENT INC | -7,789 | $1030.448 | $8,026,159 |
| 2025-11-17 | JOHNSON KIMBERLY H | +215 | $1021.7 | $219,666 |
| 2025-11-17 | JACKSON JAMERE | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Kaelin William G Jr | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Baicker Katherine | +215 | $1021.7 | $219,666 |
| 2025-11-17 | LUCIANO JUAN R | +215 | $1021.7 | $219,666 |
| 2025-11-17 | LUCIANO JUAN R | +15 | $1021.7 | $15,326 |
| 2025-11-17 | Moeller Jon R | +233 | $1021.7 | $238,056 |
| 2025-11-17 | Fyrwald J Erik | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Fyrwald J Erik | +10 | $1021.7 | $10,217 |
| 2025-11-17 | Hedley Mary Lynne | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Hedley Mary Lynne | +10 | $1021.7 | $10,217 |
| 2025-11-17 | Alvarez Ralph | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Alvarez Ralph | +12 | $1021.7 | $12,260 |
| 2025-11-17 | Sulzberger Gabrielle | +215 | $1021.7 | $219,666 |
| 2025-11-17 | Sulzberger Gabrielle | +5 | $1021.7 | $5,109 |
| 2025-11-14 | LILLY ENDOWMENT INC | -949 | $1033.155 | $980,464 |
| 2025-11-14 | LILLY ENDOWMENT INC | -17,567 | $1032319 | $18,134,747,873 |
| 2025-11-14 | LILLY ENDOWMENT INC | -55,908 | $1031414 | $57,664,293,912 |
| 2025-11-14 | LILLY ENDOWMENT INC | -103,871 | $1030.312 | $107,019,538 |
| 2025-11-13 | LILLY ENDOWMENT INC | -1,360 | $1031.777 | $1,403,217 |
| 2025-11-13 | LILLY ENDOWMENT INC | -45,246 | $1030.21 | $46,612,882 |
| 2025-11-13 | Zakrowski Donald A | -1,000 | $1010.5 | $1,010,500 |
| 2025-11-12 | LILLY ENDOWMENT INC | -842 | $1021.065 | $859,737 |
| 2025-11-12 | LILLY ENDOWMENT INC | -1,281 | $1019.919 | $1,306,516 |
| 2025-11-12 | LILLY ENDOWMENT INC | -7,833 | $1018.829 | $7,980,488 |
| 2025-11-12 | LILLY ENDOWMENT INC | -47,073 | $1018.022 | $47,921,350 |
| 2025-11-12 | LILLY ENDOWMENT INC | -7,188 | $1017.156 | $7,311,317 |
| 2025-11-12 | LILLY ENDOWMENT INC | -13,415 | $1016.005 | $13,629,707 |
| 2025-11-12 | LILLY ENDOWMENT INC | -16,274 | $1015.158 | $16,520,681 |
| 2025-11-12 | LILLY ENDOWMENT INC | -11,638 | $1014.169 | $11,802,899 |
| 2025-11-12 | LILLY ENDOWMENT INC | -16,749 | $1012.942 | $16,965,766 |
| 2025-11-12 | LILLY ENDOWMENT INC | -21,559 | $1011.961 | $21,816,867 |
| 2025-11-12 | LILLY ENDOWMENT INC | -19,892 | $1011.177 | $20,114,333 |
| 2025-11-12 | LILLY ENDOWMENT INC | -20,000 | $1009.987 | $20,199,740 |
| 2025-11-12 | LILLY ENDOWMENT INC | -17,985 | $1009 | $18,146,865 |
| 2025-11-12 | LILLY ENDOWMENT INC | -8,913 | $1007.968 | $8,984,019 |
| 2025-11-12 | LILLY ENDOWMENT INC | -16,383 | $1007.099 | $16,499,303 |
| 2025-11-12 | LILLY ENDOWMENT INC | -23,863 | $1006.017 | $24,006,584 |
| 2025-11-12 | LILLY ENDOWMENT INC | -23,568 | $1004.968 | $23,685,086 |
| 2025-11-12 | LILLY ENDOWMENT INC | -22,131 | $1004.099 | $22,221,715 |
| 2025-11-12 | LILLY ENDOWMENT INC | -7,585 | $1003.116 | $7,608,635 |
| 2025-11-12 | LILLY ENDOWMENT INC | -828 | $1001.93 | $829,598 |
| 2025-11-11 | LILLY ENDOWMENT INC | -3,384 | $999.088 | $3,380,914 |
| 2025-11-11 | LILLY ENDOWMENT INC | -5,482 | $998.294 | $5,472,648 |
| 2025-11-11 | LILLY ENDOWMENT INC | -9,387 | $997.057 | $9,359,374 |
| 2025-11-11 | LILLY ENDOWMENT INC | -12,039 | $996.381 | $11,995,431 |
| 2025-11-11 | LILLY ENDOWMENT INC | -4,664 | $995.249 | $4,641,841 |
| 2025-11-11 | LILLY ENDOWMENT INC | -5,022 | $994.121 | $4,992,476 |
| 2025-11-11 | LILLY ENDOWMENT INC | -9,879 | $993.1 | $9,810,835 |
| 2025-11-11 | LILLY ENDOWMENT INC | -9,369 | $992.013 | $9,294,170 |
| 2025-11-11 | LILLY ENDOWMENT INC | -26,761 | $991.013 | $26,520,499 |
| 2025-11-11 | LILLY ENDOWMENT INC | -33,154 | $990.191 | $32,828,792 |
| 2025-11-11 | LILLY ENDOWMENT INC | -22,127 | $989.179 | $21,887,564 |
| 2025-11-11 | LILLY ENDOWMENT INC | -4,473 | $987.909 | $4,418,917 |
| 2025-11-11 | LILLY ENDOWMENT INC | -13,678 | $987.183 | $13,502,689 |
| 2025-11-11 | LILLY ENDOWMENT INC | -30,633 | $986.183 | $30,209,744 |
| 2025-11-11 | LILLY ENDOWMENT INC | -8,877 | $985.255 | $8,746,109 |
| 2025-11-11 | LILLY ENDOWMENT INC | -11,066 | $984.039 | $10,889,376 |
| 2025-11-11 | LILLY ENDOWMENT INC | -7,503 | $983.137 | $7,376,477 |
| 2025-11-11 | LILLY ENDOWMENT INC | -2,211 | $981.851 | $2,170,873 |
| 2025-11-11 | LILLY ENDOWMENT INC | -2,068 | $980.543 | $2,027,763 |
| 2025-11-11 | LILLY ENDOWMENT INC | -3,555 | $979.651 | $3,482,659 |
| 2025-11-11 | LILLY ENDOWMENT INC | -4,433 | $978.688 | $4,338,524 |
| 2025-11-11 | LILLY ENDOWMENT INC | -4,680 | $977.439 | $4,574,415 |
| 2025-11-11 | LILLY ENDOWMENT INC | -5,759 | $976.49 | $5,623,606 |
| 2025-11-11 | LILLY ENDOWMENT INC | -8,996 | $975.461 | $8,775,247 |
| 2025-11-11 | LILLY ENDOWMENT INC | -10,114 | $974.465 | $9,855,739 |
| 2025-11-11 | LILLY ENDOWMENT INC | -11,998 | $973.475 | $11,679,753 |
| 2025-11-11 | LILLY ENDOWMENT INC | -11,819 | $972.269 | $11,491,247 |
| 2025-11-10 | LILLY ENDOWMENT INC | -118 | $974.089 | $114,943 |
| 2025-11-10 | LILLY ENDOWMENT INC | -3,887 | $973.626 | $3,784,484 |
| 2025-11-10 | LILLY ENDOWMENT INC | -12,864 | $972.168 | $12,505,969 |
| 2025-11-10 | Skovronsky Daniel | -179 | - | - |
| 2025-11-10 | Ricks David A | -24,750 | - | - |
| 2025-11-05 | LILLY ENDOWMENT INC | -1,110 | $954.948 | $1,059,992 |
| 2025-11-05 | LILLY ENDOWMENT INC | -4,699 | $953.663 | $4,481,262 |
| 2025-11-05 | LILLY ENDOWMENT INC | -10,392 | $952.887 | $9,902,402 |
| 2025-11-05 | LILLY ENDOWMENT INC | -10,200 | $952.001 | $9,710,410 |
| 2025-11-05 | LILLY ENDOWMENT INC | -2,010 | $950.937 | $1,911,383 |
| 2025-11-05 | LILLY ENDOWMENT INC | -4,495 | $949.82 | $4,269,441 |
| 2025-11-05 | LILLY ENDOWMENT INC | -5,617 | $948.822 | $5,329,533 |
| 2025-11-05 | LILLY ENDOWMENT INC | -1,909 | $947.626 | $1,809,018 |
| 2025-11-05 | LILLY ENDOWMENT INC | -3,773 | $946.399 | $3,570,763 |
| 2025-11-05 | LILLY ENDOWMENT INC | -13,007 | $945.617 | $12,299,640 |
| 2025-11-05 | LILLY ENDOWMENT INC | -12,581 | $944.677 | $11,884,981 |
| 2025-11-05 | LILLY ENDOWMENT INC | -3,820 | $943.711 | $3,604,976 |
| 2025-11-05 | LILLY ENDOWMENT INC | -1,657 | $942.306 | $1,561,401 |
| 2025-11-05 | LILLY ENDOWMENT INC | -2,759 | $941.356 | $2,597,201 |
| 2025-11-05 | LILLY ENDOWMENT INC | -3,966 | $940.623 | $3,730,511 |
| 2025-11-05 | LILLY ENDOWMENT INC | -2,790 | $939.538 | $2,621,311 |
| 2025-11-05 | LILLY ENDOWMENT INC | -3,388 | $938.433 | $3,179,411 |
| 2025-11-05 | LILLY ENDOWMENT INC | -3,731 | $937.421 | $3,497,518 |
| 2025-11-05 | LILLY ENDOWMENT INC | -5,292 | $936.567 | $4,956,313 |
| 2025-11-05 | LILLY ENDOWMENT INC | -6,386 | $935.26 | $5,972,570 |
| 2025-11-05 | LILLY ENDOWMENT INC | -9,209 | $934.206 | $8,603,103 |
| 2025-11-05 | LILLY ENDOWMENT INC | -6,642 | $933.292 | $6,198,925 |
| 2025-11-05 | LILLY ENDOWMENT INC | -12,924 | $932.274 | $12,048,709 |
| 2025-11-05 | LILLY ENDOWMENT INC | -10,938 | $931.245 | $10,185,958 |
| 2025-11-05 | LILLY ENDOWMENT INC | -5,528 | $930.222 | $5,142,267 |
| 2025-11-05 | LILLY ENDOWMENT INC | -15,230 | $929.423 | $14,155,112 |
| 2025-11-05 | LILLY ENDOWMENT INC | -4,457 | $928.2 | $4,136,987 |
| 2025-11-05 | LILLY ENDOWMENT INC | -8,409 | $927.12 | $7,796,152 |
| 2025-11-05 | LILLY ENDOWMENT INC | -31,016 | $925.872 | $28,716,846 |
| 2025-11-05 | LILLY ENDOWMENT INC | -550 | $924.352 | $508,394 |
| 2025-11-05 | LILLY ENDOWMENT INC | -2,635 | $923.46 | $2,433,317 |
| 2025-11-05 | LILLY ENDOWMENT INC | -4,434 | $922.416 | $4,089,993 |
| 2025-11-05 | LILLY ENDOWMENT INC | -2,090 | $921.496 | $1,925,927 |
| 2025-11-05 | LILLY ENDOWMENT INC | -160 | $918.12 | $146,899 |
| 2025-11-05 | LILLY ENDOWMENT INC | -230 | $917.264 | $210,971 |
| 2025-11-05 | LILLY ENDOWMENT INC | -550 | $915.333 | $503,433 |
| 2025-11-05 | LILLY ENDOWMENT INC | -620 | $913.778 | $566,542 |
| 2025-11-05 | LILLY ENDOWMENT INC | -270 | $911.005 | $245,971 |
| 2025-11-04 | LILLY ENDOWMENT INC | -526 | $910.719 | $479,038 |
| 2025-11-03 | LILLY ENDOWMENT INC | -1,633 | $900.794 | $1,470,997 |
| 2025-11-03 | LILLY ENDOWMENT INC | -4,474 | $900.017 | $4,026,676 |
| 2025-11-03 | LILLY ENDOWMENT INC | -5,391 | $899.18 | $4,847,479 |
| 2025-11-03 | LILLY ENDOWMENT INC | -19,295 | $898.203 | $17,330,827 |
| 2025-11-03 | LILLY ENDOWMENT INC | -11,842 | $897.195 | $10,624,583 |
| 2025-11-03 | LILLY ENDOWMENT INC | -29,709 | $896.146 | $26,623,602 |
| 2025-11-03 | LILLY ENDOWMENT INC | -17,639 | $895.155 | $15,789,639 |
| 2025-11-03 | LILLY ENDOWMENT INC | -17,537 | $894.327 | $15,683,813 |
| 2025-11-03 | LILLY ENDOWMENT INC | -4,246 | $893.35 | $3,793,164 |
| 2025-11-03 | LILLY ENDOWMENT INC | -17,299 | $891.973 | $15,430,241 |
| 2025-11-03 | LILLY ENDOWMENT INC | -15,508 | $891.172 | $13,820,295 |
| 2025-11-03 | LILLY ENDOWMENT INC | -14,867 | $890.2 | $13,234,603 |
| 2025-11-03 | LILLY ENDOWMENT INC | -2,452 | $888.959 | $2,179,727 |
| 2025-11-03 | LILLY ENDOWMENT INC | -4,081 | $888.142 | $3,624,508 |
| 2025-11-03 | LILLY ENDOWMENT INC | -3,038 | $886.287 | $2,692,540 |
| 2025-11-03 | LILLY ENDOWMENT INC | -21,884 | $885.557 | $19,379,529 |
| 2025-11-03 | LILLY ENDOWMENT INC | -26,340 | $884.665 | $23,302,076 |
| 2025-11-03 | LILLY ENDOWMENT INC | -10,681 | $883.746 | $9,439,291 |
| 2025-11-03 | LILLY ENDOWMENT INC | -4,226 | $882.32 | $3,728,684 |
| 2025-11-03 | LILLY ENDOWMENT INC | -6,373 | $881.461 | $5,617,551 |
| 2025-11-03 | LILLY ENDOWMENT INC | -10,549 | $880.449 | $9,287,857 |
| 2025-11-03 | LILLY ENDOWMENT INC | -6,125 | $879.36 | $5,386,080 |
| 2025-11-03 | LILLY ENDOWMENT INC | -18,815 | $878.356 | $16,526,268 |
| 2025-11-03 | LILLY ENDOWMENT INC | -25,996 | $877.4 | $22,808,890 |
| 2025-10-31 | LILLY ENDOWMENT INC | -2,910 | $869.466 | $2,530,146 |
| 2025-10-31 | LILLY ENDOWMENT INC | -5,440 | $868.442 | $4,724,324 |
| 2025-10-31 | LILLY ENDOWMENT INC | -4,602 | $867.544 | $3,992,437 |
| 2025-10-31 | LILLY ENDOWMENT INC | -10,358 | $866.547 | $8,975,694 |
| 2025-10-31 | LILLY ENDOWMENT INC | -10,356 | $865.596 | $8,964,112 |
| 2025-10-31 | LILLY ENDOWMENT INC | -15,671 | $864.528 | $13,548,018 |
| 2025-10-31 | LILLY ENDOWMENT INC | -54,191 | $863.424 | $46,789,810 |
| 2025-10-31 | LILLY ENDOWMENT INC | -197,814 | $862.631 | $170,640,489 |
| 2025-10-20 | LUCIANO JUAN R | +18 | $808.96 | $14,561 |
| 2025-10-20 | Fyrwald J Erik | +12 | $808.96 | $9,708 |
| 2025-10-20 | Hedley Mary Lynne | +12 | $808.96 | $9,708 |
| 2025-10-20 | Alvarez Ralph | +15 | $808.96 | $12,134 |
| 2025-10-20 | Sulzberger Gabrielle | +6 | $808.96 | $4,854 |
| 2025-10-10 | LILLY ENDOWMENT INC | -3,190 | $863.369 | $2,754,147 |
| 2025-10-10 | LILLY ENDOWMENT INC | -468 | $862.34 | $403,575 |
| 2025-10-09 | LILLY ENDOWMENT INC | -200 | $857.255 | $171,451 |
| 2025-10-09 | LILLY ENDOWMENT INC | -835 | $854.956 | $713,888 |
| 2025-10-09 | LILLY ENDOWMENT INC | -1,473 | $854.605 | $1,258,833 |
| 2025-10-09 | LILLY ENDOWMENT INC | -1,247 | $853.197 | $1,063,937 |
| 2025-10-09 | LILLY ENDOWMENT INC | -2,472 | $852.207 | $2,106,656 |
| 2025-10-09 | LILLY ENDOWMENT INC | -3,375 | $851.583 | $2,874,093 |
| 2025-10-09 | LILLY ENDOWMENT INC | -400 | $850.05 | $340,020 |
| 2025-10-09 | LILLY ENDOWMENT INC | -600 | $848.63 | $509,178 |
| 2025-10-08 | LILLY ENDOWMENT INC | -200 | $856 | $171,200 |
| 2025-10-08 | LILLY ENDOWMENT INC | -946 | $854.639 | $808,488 |
| 2025-10-08 | LILLY ENDOWMENT INC | -3,881 | $853.846 | $3,313,776 |
| 2025-10-08 | LILLY ENDOWMENT INC | -3,227 | $852.361 | $2,750,569 |
| 2025-10-08 | LILLY ENDOWMENT INC | -13,624 | $851.403 | $11,599,514 |
| 2025-10-08 | LILLY ENDOWMENT INC | -36,114 | $850.519 | $30,715,643 |
| 2025-10-08 | LILLY ENDOWMENT INC | -25,296 | $849.597 | $21,491,406 |
| 2025-10-08 | LILLY ENDOWMENT INC | -18,132 | $848.46 | $15,384,277 |
| 2025-10-07 | LILLY ENDOWMENT INC | -26,795 | $848.009 | $22,722,401 |
| 2025-10-06 | LILLY ENDOWMENT INC | -2,399 | $855.711 | $2,052,851 |
| 2025-10-06 | LILLY ENDOWMENT INC | -7,143 | $854.543 | $6,104,001 |
| 2025-10-06 | LILLY ENDOWMENT INC | -14,822 | $853.645 | $12,652,726 |
| 2025-10-06 | LILLY ENDOWMENT INC | -9,767 | $852.673 | $8,328,057 |
| 2025-10-06 | LILLY ENDOWMENT INC | -12,180 | $851.582 | $10,372,269 |
| 2025-10-06 | LILLY ENDOWMENT INC | -22,960 | $850.647 | $19,530,855 |
| 2025-10-06 | LILLY ENDOWMENT INC | -28,063 | $849.443 | $23,837,919 |
| 2025-10-06 | LILLY ENDOWMENT INC | -63,849 | $848.298 | $54,162,979 |
| 2025-10-03 | LILLY ENDOWMENT INC | -405 | $847.601 | $343,278 |
| 2025-10-03 | LILLY ENDOWMENT INC | -4,870 | $847.026 | $4,125,017 |
| 2025-10-03 | LILLY ENDOWMENT INC | -3,893 | $845.821 | $3,292,781 |
| 2025-10-03 | LILLY ENDOWMENT INC | -10,135 | $845.069 | $8,564,774 |
| 2025-10-03 | LILLY ENDOWMENT INC | -7,114 | $843.643 | $6,001,676 |
| 2025-10-03 | LILLY ENDOWMENT INC | -10,040 | $842.946 | $8,463,178 |
| 2025-10-03 | LILLY ENDOWMENT INC | -11,316 | $841.701 | $9,524,689 |
| 2025-10-03 | LILLY ENDOWMENT INC | -24,495 | $840.74 | $20,593,926 |
| 2025-10-03 | LILLY ENDOWMENT INC | -31,102 | $839.939 | $26,123,783 |
| 2025-10-03 | LILLY ENDOWMENT INC | -7,894 | $838.857 | $6,621,937 |
| 2025-10-03 | LILLY ENDOWMENT INC | -22,843 | $837.781 | $19,137,431 |
| 2025-10-03 | LILLY ENDOWMENT INC | -16,792 | $836.862 | $14,052,587 |
| 2025-10-03 | LILLY ENDOWMENT INC | -8,203 | $835.769 | $6,855,813 |
| 2025-10-03 | LILLY ENDOWMENT INC | -3,509 | $834.764 | $2,929,187 |
| 2025-10-03 | LILLY ENDOWMENT INC | -2,204 | $833.828 | $1,837,757 |
| 2025-10-03 | LILLY ENDOWMENT INC | -300 | $831.05 | $249,315 |
| 2025-10-03 | LILLY ENDOWMENT INC | -872 | $829.858 | $723,636 |
| 2025-10-03 | LILLY ENDOWMENT INC | -200 | $828.5 | $165,700 |
| 2025-10-03 | LILLY ENDOWMENT INC | -952 | $827.405 | $787,690 |
| 2025-10-03 | LILLY ENDOWMENT INC | -4,150 | $826.739 | $3,430,967 |
| 2025-10-03 | LILLY ENDOWMENT INC | -2,804 | $825.533 | $2,314,795 |
| 2025-10-03 | LILLY ENDOWMENT INC | -9,823 | $824.68 | $8,100,832 |
| 2025-10-03 | LILLY ENDOWMENT INC | -2,644 | $823.648 | $2,177,725 |
| 2025-10-03 | LILLY ENDOWMENT INC | -1,558 | $822.42 | $1,281,330 |
| 2025-10-03 | LILLY ENDOWMENT INC | -4,286 | $821.418 | $3,520,598 |